Bio-Path Holdings Reports Fiscal Year 2013 Operational and Financial Results

Published April 1, 2014

Bio-Path Holdings Reports Fiscal Year 2013 Operational and Financial Results
The drug's safety profile continues to be favorable with no treatment-related serious adverse events reported and data continues to suggest possible anti-leukemia activity. The trial is being conducted at The University of Texas MD Anderson Cancer …
Read more on Business Wire (press release)

DURECT Announces POSIDUR™ (SABER®-Bupivacaine) Data Presentations …
CUPERTINO, Calif., April 1, 2014 /PRNewswire/ — DURECT Corporation (NASDAQ:DRRX) today announced that data for POSIDUR™ (SABER®-Bupivacaine), an investigational drug for administration into the surgical site to produce post-surgical analgesia, is …
Read more on MarketWatch

SGO Wrap-Up: Obesity, New Drug, No-Admit Surgery
SGO Wrap-Up: Obesity, New Drug, No-Admit Surgery. Published: Mar 31, 2014 … Because obesity can complicate management of the disease, better understanding of the two treatment strategies' risks and benefits might improve outcomes, noted Michael J …
Read more on MedPage Today

Rehab Center Houston TX | Treatment Centers in Houston | Rehab Center Houston TX — http://rehabcentersinhouston.org Get therapy, sober living assistance, aftercare, detox, and more at Rehab Center Houston TX for drug, alcohol, and pharmaceu…

More Drug Treatment Centers Houston Texas Information…